CPRX - Catalyst Pharmaceuticals Inc. (CPRX) Q1 2024 Earnings Call Transcript
2024-05-09 10:52:07 ET
Catalyst Pharmaceuticals, Inc. (CPRX)
Q1 2024 Earnings Conference Call
May 9, 2024 8:30 a.m. ET
Company Participants
Michael Kalb - Chief Financial Officer
Richard Daly - President and Chief Executive Officer
Jeffrey Del Carmen - Chief Commercial Officer
Steven Miller - Chief Operating Officer and Chief Scientific Officer
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Jason Gerberry - Bank of America
Joe Catanzaro - Piper Sandler
Presentation
Operator
Greetings, and welcome to the Catalyst Pharmaceuticals' First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Mike Kalb, Chief Financial Officer. Thank you, sir. You may begin.
Michael Kalb
Thank you. Good morning, everyone, and thank you for joining our conference call to discuss Catalyst's first quarter 2024 financial results and business highlights. Richard Daly, President and CEO will be leading the call today, and Jeffrey Del Carmen, our Chief Commercial Officer, and I will also be presenting. Additionally, Dr. Steven Miller, our Chief Operating Officer and Chief Scientific Officer will be available for the Q&A.
Before we begin, I would like to remind you that in our remarks this morning and in the Q&A session, we will make statements about expected future results, which may be forward-looking statements for purposes of federal securities laws. These statements relate to our current expectations, estimates, and projections, and are not guarantees of future performance. They involve risks, uncertainties, and assumptions that are difficult to predict and may not prove to be accurate. Actual results may vary from the expectations contained in our forward-looking statements.
These forward-looking statements should be considered only in conjunction with the detailed information contained in our SEC filings including the risk factors described in our 2023 annual report on Form 10-K filed with the SEC on February 28th 2024 and in our first quarter 2024 quarterly report on Form 10-Q which we filed yesterday with the SEC....
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript